Efficacy, Moderators and Mediators of CBASP Versus BA in Treatment-Resistant Persistent Depressi

A Pragmatic Inquiry into Inpatient Treatments for Persistent Depression: CBASP vs BA

CBASP is highlighted as the only psychotherapy developed specifically for PDD, with prior outpatient evidence but limited inpatient data.

BA is presented as a first-line depressive disorder therapy used as an active comparator.

• The article outlines a multicentre randomized controlled trial (RCT) designed to compare two psychotherapies for treatment-resistant persistent depressive disorder (PDD) in an inpatient setting.

• Design: Prospective, multicentre, rater-blinded RCT with an active control.
• Setting: Eight German university hospitals.
• Participants: Adults aged 18 to 70 years meeting criteria for treatment-resistant PDD.
• Intervention framework: Both arms are embedded in an intensive multimodal program consisting of a 10-week acute phase in inpatient and/or day clinic settings, followed by 6 weeks of outpatient continuation treatment.
• Randomization and control: Participants are randomly assigned to CBASP or BA, with assessors blinded to treatment allocation.

• CBASP arm: Structured psychotherapy tailored for PDD, delivered within the intensive program framework.
• BA arm: Behavioral Activation, delivered within the same multimodal context to ensure an active comparison.
• Treatment period: 16 weeks of structured intervention (10 weeks acute phase plus 6 weeks continuation).

• Primary outcome: Change in depression severity measured by the 24-item Hamilton Depression Rating Scale (HAM-D) from baseline to week 16 (T0 to T4), i.e., after the completion of the acute plus continuation phases.
• Secondary outcomes: Rates of response, remission, deterioration, and relapse; self-reported depression and anxiety; additional psychological variables; and a health-economic cost-benefit analysis.
• Follow-up: Naturalistic follow-up extending to week 64, with assessments at multiple intervals (T5 and beyond) to capture longer-term trajectories.

• Economic analysis: A cost-benefit component is included to assess health-economic implications of CBASP versus BA.
• Moderation and mediation: The study aims to identify moderators and mediators of treatment effects to illuminate factors associated with differential efficacy and potential mechanisms of change.
• Personalization: Exploration of predictors to guide future treatment selection between CBASP and BA for individual inpatients with treatment-resistant PDD.

• Ethics: The trial has received approval from ethics committees at all participating sites.
• Informed consent: Written consent is required from all participants prior to enrollment.
• Patient engagement: Individuals with lived experience contributed to study design from early pilot stages, with ongoing patient-centered input through conferences and public events.

• Publication plan: Findings are intended for peer-reviewed journals, with dissemination at national and international conferences.
• Clinical relevance: The trial seeks to equip clinicians with evidence-based guidance on choosing between CBASP and BA for inpatients with treatment-resistant PDD, addressing an evidence gap in inpatient settings.

• The provided content does not specify sample size beyond the planned 396 participants, nor does it report preliminary results, safety signal details, or exact operational definitions for some secondary outcomes.